Dr. Kabos’ interest is in translating preclinical findings into novel treatments for patients with breast cancer. The Kabos lab focuses on the role of breast cancer stem cells and tumor microenvironment in treatment resistance.
Kabos P, Dye WW, Elias A, Horwitz KB, Sartorius CA. Rare ER-/CK5+ cells in luminal type human breast cancers are resistant to hormone therapy and chemotherapy and repopulate ER+ tumors. AACR 100th Annual Meeting 2009, Denver, CO, Abstract # 7489 (oral presentation)
Horwitz KB, Dye WW, Harrell JC, Kabos P, Sartorius CA. Rare steroid receptor-negative basal-like tumorigenic cells in luminal subtype human breast cancer xenografts. PNAS. 2008 April 15, 105(15): 5774–5779. PMID 18391223
Ehtesham M, Winston JA, Kabos P, Thompson RC. CXCR4 expression mediates glioma cell invasiveness. Oncogene. 2006 May 4;25(19):2801-2806. PMID 16407848
Kabos P, Kabosova A, Neuman T. Blocking HES1 expression initiates GABAergic differentiation and induces the expression of p21(CIP1/WAF1) in human neural stem cells. J Biol Chem. 2002 Mar 15;277(11):8763-8766. PMID 11809764